Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology

Abstract

The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

1 . A vaccine for the prophylaxis or treatment of an allergen-driven airway pathology, said vaccine comprising a live attenuated  Bordetella pertussis  strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) 
     
     
         2 . The vaccine according to  claim 1 , wherein the allergen-driven airway pathology is selected from the group consisting of allergic asthma, Hay fever and interstitial lung diseases. 
     
     
         3 . The vaccine according to  claim 1 , wherein the subject is a neonate or an infant. 
     
     
         4 . The vaccine according to  claim 1 , wherein the live attenuated  Bordetella pertussis  vaccine is the BPZE1 strain. 
     
     
         5 . The vaccine according to  claim 1 , wherein the live attenuated  Bordetella pertussis  strain comprises a heterologous antigen. 
     
     
         6 . A live life attenuated  Bordetella pertussis  vaccine according to  claim 1 , wherein the live attenuated  Bordetella pertussis  vaccine is administered by nasal administration or by inhalation. 
     
     
         7 . The vaccine according to  claim 1 , wherein the vaccine comprises an adjuvant and a pharmaceutically acceptable carrier or diluent. 
     
     
         8 . A method of vaccination or treatment of an allergen driven airway pathology in a subject comprising administering to said subject a composition comprising a vaccine of  claim 1 . 
     
     
         9 . The method of  claim 8  wherein the allergen-driven airway pathology is selected from the group consisting of allergic asthma, Hay fever and interstitial lung diseases. 
     
     
         10 . The method of  claim 8 , wherein the subject is a neonate or an infant. 
     
     
         11 . The method of  claim 8 , wherein the live attenuated  Bordetella pertussis  vaccine comprises the BPZE1 strain. 
     
     
         12 . The method of  claim 8 , wherein the live attenuated  Bordetella pertussis  vaccine comprises a heterologous antigen. 
     
     
         13 . The method of  claim 8 , wherein the live attenuated  Bordetella pertussis  vaccine is administered by nasal administration or by inhalation. 
     
     
         14 . A method for the preparation of a vaccine for the prophylaxis or treatment of an allergen-driven airway pathology comprising preparing a live  Bordetella pertussis  strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) and admixing said  Bordetella pertussis  strain with and adjuvant and/or a pharmaceutically acceptable carrier or diluent for nasal or inhalational administration. 
     
     
         15 . The method of  claim 14  wherein the allergen-driven airway pathology is selected from the group consisting of allergic asthma, Hay fever and interstitial lung diseases. 
     
     
         16 . The method of  claim 14 , wherein the live attenuated  Bordetella pertussis  vaccine comprises the BPZE1 strain and optionally, wherein the live attenuated  Bordetella pertussis  vaccine comprises a heterologous antigen. 
     
     
         17 . A method of protecting a subject from an allergen-driven airway pathology comprising administering to said subject a vaccine comprising a live  Bordetella pertussis  strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) in an amount effective to vaccinate against said allergen-driven airway pathology. 
     
     
         18 . The method of  claim 17  wherein the allergen-driven airway pathology is selected from the group consisting of allergic asthma, Hay fever and interstitial lung diseases. 
     
     
         19 . The method of  claim 17 , wherein the live attenuated  Bordetella pertussis  vaccine comprises the BPZE1 strain and optionally, wherein the live attenuated  Bordetella pertussis  vaccine comprises a heterologous antigen.